Sellas Life Sciences announces proposed public offering of common stock

ELLAS Life Sciences “announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by SELLAS. The Company intends to use the net proceeds from the offering for funding of ongoing operations, including clinical development of existing product candidates, and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering on a best-efforts basis. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.”